Name:
Pulmonary Arterial Hypertension
Description:
The PROSERA Study is a randomised double-blind global Phase 3 clinical research study designed to help researchers understand whether an inhaled investigational product called seralutinib may be an effective and safe future treatment for adults with pulmonary arterial hypertension. The goal is to understand the effect of seralutinib on specific pathways in the body that lead to the inflammation, proliferation and fibrosis associated with pulmonary arterial hypertension. Currently there is no treatment available that targets these specific pathways collectively. Further Information
Stage:
Recruiting
Principal Investigator:
Professor Sean Gaine
Sponsor:
Gossamer Bio
Network Partners
